{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T22:12:11Z","timestamp":1793657531877,"version":"4.5.1"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1245\/s10434-025-19070-2","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T17:57:52Z","timestamp":1768586272000},"page":"4453-4462","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Oncologic Outcomes of Sentinel Lymph Node Biopsy Versus Targeted Axillary Dissection for Node-Positive Breast Cancer Patients After Neoadjuvant Chemotherapy: A Systematic Review and Meta-Analysis"],"prefix":"10.1245","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9382-5180","authenticated-orcid":false,"given":"Hussain A.","family":"Abdulla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"McGarry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roza","family":"Kaczorowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Grealish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire L.","family":"Rutherford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damian","family":"McCartan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Evoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Rothwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth S.","family":"Prichard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Boland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,16]]},"reference":[{"key":"19070_CR1","doi-asserted-by":"publisher","first-page":"4515","DOI":"10.1245\/s10434-020-08650-z","volume":"27","author":"G Montagna","year":"2020","unstructured":"Montagna G, Mamtani A, Knezevic A, et al. Selecting node-positive patients for axillary downstaging with neoadjuvant chemotherapy. Ann Surg Oncol. 2020;27:4515\u201322. https:\/\/doi.org\/10.1245\/s10434-020-08650-z.","journal-title":"Ann Surg Oncol."},{"key":"19070_CR2","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s10549-018-5004-7","volume":"173","author":"JM Classe","year":"2019","unstructured":"Classe JM, Loaec C, Gimbergues P, et al. Sentinel lymph node biopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients: the GANEA 2 study. Breast Cancer Res Treat. 2019;173:343\u201352. https:\/\/doi.org\/10.1007\/s10549-018-5004-7.","journal-title":"Breast Cancer Res Treat."},{"key":"19070_CR3","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1001\/jama.2013.278932","volume":"310","author":"JC Boughey","year":"2013","unstructured":"Boughey JC, Suman VJ, Mittendorf EA, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013;310:1455\u201361. https:\/\/doi.org\/10.1001\/jama.2013.278932.","journal-title":"JAMA."},{"key":"19070_CR4","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/s1470-2045(13)70166-9","volume":"14","author":"T Kuehn","year":"2013","unstructured":"Kuehn T, Bauerfeind I, Fehm T, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol. 2013;14:609\u201318. https:\/\/doi.org\/10.1016\/s1470-2045(13)70166-9.","journal-title":"Lancet Oncol."},{"key":"19070_CR5","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1200\/jco.2014.55.7827","volume":"33","author":"JF Boileau","year":"2015","unstructured":"Boileau JF, Poirier B, Basik M, et al. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. J Clin Oncol. 2015;33:258\u201364. https:\/\/doi.org\/10.1200\/jco.2014.55.7827.","journal-title":"J Clin Oncol."},{"key":"19070_CR6","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1200\/jco.2015.64.0094","volume":"34","author":"AS Caudle","year":"2016","unstructured":"Caudle AS, Yang WT, Krishnamurthy S, et al. Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection. J Clin Oncol. 2016;34:1072\u20138. https:\/\/doi.org\/10.1200\/jco.2015.64.0094.","journal-title":"J Clin Oncol."},{"key":"19070_CR7","doi-asserted-by":"publisher","first-page":"331","DOI":"10.6004\/jnccn.2024.0035","volume":"22","author":"WJ Gradishar","year":"2024","unstructured":"Gradishar WJ, Moran MS, Abraham J, et al. Breast cancer, Version 3.2024, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2024;22:331\u201357. https:\/\/doi.org\/10.6004\/jnccn.2024.0035.","journal-title":"J Natl Compr Canc Netw."},{"key":"19070_CR8","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1016\/j.annonc.2021.06.023","volume":"32","author":"HJ Burstein","year":"2021","unstructured":"Burstein HJ, Curigliano G, Th\u00fcrlimann B, et al. Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. Ann Oncol. 2021;32:1216\u201335. https:\/\/doi.org\/10.1016\/j.annonc.2021.06.023.","journal-title":"Ann Oncol."},{"key":"19070_CR9","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1245\/s10434-020-08928-2","volume":"28","author":"MF Almahariq","year":"2021","unstructured":"Almahariq MF, Levitin R, Quinn TJ, et al. Omission of axillary lymph node dissection is associated with inferior survival in breast cancer patients with residual N1 nodal disease following neoadjuvant chemotherapy. Ann Surg Oncol. 2021;28:930\u201340. https:\/\/doi.org\/10.1245\/s10434-020-08928-2.","journal-title":"Ann Surg Oncol."},{"key":"19070_CR10","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ejso.2019.08.012","volume":"46","author":"JM Simons","year":"2020","unstructured":"Simons JM, Maaskant-Braat AJG, Luiten EJT, et al. Patterns of axillary staging and management in clinically node-positive breast cancer patients treated with neoadjuvant systemic therapy: results of a survey amongst breast cancer specialists. Eur J Surg Oncol. 2020;46:53\u20138. https:\/\/doi.org\/10.1016\/j.ejso.2019.08.012.","journal-title":"Eur J Surg Oncol."},{"key":"19070_CR11","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.3390\/cancers13071565","volume":"13","author":"M Banys-Paluchowski","year":"2021","unstructured":"Banys-Paluchowski M, Gasparri ML, de Boniface J, et al. Surgical management of the axilla in clinically node-positive breast cancer patients converting to clinical node negativity through neoadjuvant chemotherapy: current status, knowledge gaps, and rationale for the EUBREAST-03 AXSANA study. Cancers Basel. 2021;13:1565. https:\/\/doi.org\/10.3390\/cancers13071565.","journal-title":"Cancers Basel."},{"key":"19070_CR12","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1093\/bjs\/znac217","volume":"109","author":"ML Gasparri","year":"2022","unstructured":"Gasparri ML, de Boniface J, Poortmans P, et al. Axillary surgery after neoadjuvant therapy in initially node-positive breast cancer: international EUBREAST survey. Br J Surg. 2022;109:857\u201363. https:\/\/doi.org\/10.1093\/bjs\/znac217.","journal-title":"Br J Surg."},{"key":"19070_CR13","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1097\/SLA.0000000000003075","volume":"269","author":"JM Simons","year":"2019","unstructured":"Simons JM, van Nijnatten TJA, van der Pol CC, et al. Diagnostic accuracy of different surgical procedures for axillary staging after neoadjuvant systemic therapy in node-positive breast cancer: a systematic review and meta-analysis. Ann Surg. 2019;269:432\u201342. https:\/\/doi.org\/10.1097\/SLA.0000000000003075.","journal-title":"Ann Surg."},{"key":"19070_CR14","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.breast.2023.06.011","volume":"71","author":"AKE van Hemert","year":"2023","unstructured":"van Hemert AKE, van Duijnhoven FH, Vrancken Peeters MTFD. This house believes that: MARI\/TAD is better than sentinel node biopsy after PST for cN+ patients. Breast. 2023;71:89\u201395. https:\/\/doi.org\/10.1016\/j.breast.2023.06.011.","journal-title":"Breast."},{"key":"19070_CR15","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.breast.2022.12.010","volume":"67","author":"V Galimberti","year":"2023","unstructured":"Galimberti V, Ribeiro Fontana SK, Vicini E, et al. This house believes that: Sentinel node biopsy alone is better than TAD after NACT for cN+ patients. Breast. 2023;67:21\u20135. https:\/\/doi.org\/10.1016\/j.breast.2022.12.010.","journal-title":"Breast."},{"key":"19070_CR16","doi-asserted-by":"publisher","first-page":"6133","DOI":"10.1245\/s10434-022-12240-6","volume":"29","author":"G Montagna","year":"2022","unstructured":"Montagna G, Lee MK, Sevilimedu V, et al. Is nodal clipping beneficial for node-positive breast cancer patients receiving neoadjuvant chemotherapy? Ann Surg Oncol. 2022;29:6133\u20139. https:\/\/doi.org\/10.1245\/s10434-022-12240-6.","journal-title":"Ann Surg Oncol."},{"key":"19070_CR17","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1016\/j.ejso.2018.05.035","volume":"44","author":"S Hartmann","year":"2018","unstructured":"Hartmann S, Reimer T, Gerber B, et al. Wire localization of clip-marked axillary lymph nodes in breast cancer patients treated with primary systemic therapy. Eur J Surg Oncol. 2018;44:1307\u201311. https:\/\/doi.org\/10.1016\/j.ejso.2018.05.035.","journal-title":"Eur J Surg Oncol."},{"key":"19070_CR18","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1001\/jamaoncol.2021.4394","volume":"7","author":"AV Barrio","year":"2021","unstructured":"Barrio AV, Montagna G, Mamtani A, et al. Nodal recurrence in patients with node-positive breast cancer treated with sentinel node biopsy alone after neoadjuvant chemotherapy-a rare event. JAMA Oncol. 2021;7:1851\u20135. https:\/\/doi.org\/10.1001\/jamaoncol.2021.4394.","journal-title":"JAMA Oncol."},{"key":"19070_CR19","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/j.ejso.2020.10.014","volume":"47","author":"S Kahler-Ribeiro-Fontana","year":"2021","unstructured":"Kahler-Ribeiro-Fontana S, Pagan E, Magnoni F, et al. Long-term standard sentinel node biopsy after neoadjuvant treatment in breast cancer: a single-institution ten-year follow-up. Eur J Surg Oncol. 2021;47:804\u201312. https:\/\/doi.org\/10.1016\/j.ejso.2020.10.014.","journal-title":"Eur J Surg Oncol."},{"key":"19070_CR20","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1093\/bjs\/znac413","volume":"110","author":"S Keelan","year":"2023","unstructured":"Keelan S, Boland MR, Ryan \u00c9J, et al. Long-term survival in patients with node-positive breast cancer who undergo sentinel lymph node biopsy alone after neoadjuvant chemotherapy: meta-analysis. Br J Surg. 2023;110:324\u201332. https:\/\/doi.org\/10.1093\/bjs\/znac413.","journal-title":"Br J Surg."},{"key":"19070_CR21","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1001\/jamasurg.2023.1772","volume":"158","author":"S Kuemmel","year":"2023","unstructured":"Kuemmel S, Heil J, Bruzas S, et al. Safety of targeted axillary dissection after neoadjuvant therapy in patients with node-positive breast cancer. JAMA Surg. 2023;158:807\u201315. https:\/\/doi.org\/10.1001\/jamasurg.2023.1772.","journal-title":"JAMA Surg."},{"key":"19070_CR22","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.clon.2019.05.021","volume":"31","author":"A Gandhi","year":"2019","unstructured":"Gandhi A, Coles C, Makris A, et al. Axillary surgery following neoadjuvant chemotherapy: multidisciplinary guidance from the association of breast surgery. Faculty of Clinical Oncology of the Royal College of Radiologists, UK Breast Cancer Group, National Coordinating Committee for Breast Pathology, and British Society of Breast Radiology. Clin Oncol R Coll Radiol. 2019;31:664\u20138. https:\/\/doi.org\/10.1016\/j.clon.2019.05.021.","journal-title":"Clin Oncol R Coll Radiol."},{"key":"19070_CR23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS600","author":"EP Mamounas","year":"2019","unstructured":"Mamounas EP, Bandos H, White JR, et al. NRG Oncology\/NSABP B-51\/RTOG 1304: phase III trial to determine if chest wall and regional nodal radiotherapy (CWRNRT) post mastectomy (Mx) or the addition of RNRT to whole-breast RT post-breast-conserving surgery (BCS) reduces invasive breast cancer recurrence-free interval (IBCR-FI) in patients (pts) with pathologically positive axillary (PPAx) nodes who are ypN0 after neoadjuvant chemotherapy (NC). J Clin Oncol. 2019. https:\/\/doi.org\/10.1200\/JCO.2019.37.15_suppl.TPS600.","journal-title":"J Clin Oncol."},{"key":"19070_CR24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS615","author":"A Goyal","year":"2022","unstructured":"Goyal A, Cramp S, Marshall A, et al. ATNEC: a multicenter, randomized trial investigating whether axillary treatment can be avoided in patients with T1\u20133N1M0 breast cancer with no residual cancer in the lymph glands after neoadjuvant chemotherapy. J Clin Oncol. 2022. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.TPS615.","journal-title":"J Clin Oncol."},{"key":"19070_CR25","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1001\/jamaoncol.2024.0578","volume":"10","author":"G Montagna","year":"2024","unstructured":"Montagna G, Mrdutt MM, Sun SX, et al. Omission of axillary dissection following nodal downstaging with neoadjuvant chemotherapy. JAMA Oncol. 2024;10:793\u20138. https:\/\/doi.org\/10.1001\/jamaoncol.2024.0578.","journal-title":"JAMA Oncol."},{"key":"19070_CR26","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1001\/jamasurg.2024.5913","volume":"160","author":"N Cabioglu","year":"2025","unstructured":"Cabioglu N, Ko\u00e7er HB, Karanlik H, et al. De-escalation of nodal surgery in clinically node-positive breast cancer. JAMA Surg. 2025;160:257\u201366. https:\/\/doi.org\/10.1001\/jamasurg.2024.5913.","journal-title":"JAMA Surg."},{"key":"19070_CR27","doi-asserted-by":"publisher","first-page":"4381","DOI":"10.1245\/s10434-024-15292-y","volume":"31","author":"A Pfob","year":"2024","unstructured":"Pfob A, Kokh DB, Surovtsova I, et al. Oncologic outcomes for different axillary staging techniques in patients with nodal-positive breast cancer undergoing neoadjuvant systematic treatment: a cancer registry study. Ann Surg Oncol. 2024;31:4381\u201392.","journal-title":"Ann Surg Oncol."},{"key":"19070_CR28","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1245\/s10434-024-16625-7","volume":"32","author":"A Laws","year":"2025","unstructured":"Laws A, Leonard S, Vincuilla J, et al. Risk of surgical overtreatment in cN1 breast cancer patients who become ypN0 after neoadjuvant chemotherapy: SLNB versus TAD. Ann Surg Oncol. 2025;32:2023\u20138. https:\/\/doi.org\/10.1245\/s10434-024-16625-7.","journal-title":"Ann Surg Oncol."},{"key":"19070_CR29","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-025-17197-w","author":"MK Boyle","year":"2025","unstructured":"Boyle MK, Amersi F, Chung A, et al. Comparison of targeted axillary dissection with sentinel node biopsy alone on nodal recurrence for patients who have node-positive breast cancer treated with neoadjuvant chemotherapy. Ann Surg Oncol. 2025. https:\/\/doi.org\/10.1245\/s10434-025-17197-w.","journal-title":"Ann Surg Oncol."},{"key":"19070_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2025.109689","author":"J Lucocq","year":"2025","unstructured":"Lucocq J, Baig H, McNeill E, et al. The efficacy and oncological safety of minimally invasive axillary procedures in patients with node-positive breast cancer receiving neoadjuvant chemotherapy: a network meta-regression and trial sequential analysis. Eur J Surg Oncol. 2025. https:\/\/doi.org\/10.1016\/j.ejso.2025.109689.","journal-title":"Eur J Surg Oncol."},{"key":"19070_CR31","doi-asserted-by":"publisher","first-page":"2694","DOI":"10.1200\/JCO.2005.05.188","volume":"23","author":"EP Mamounas","year":"2005","unstructured":"Mamounas EP, Brown A, Anderson S, et al. Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2005;23:2694\u2013702. https:\/\/doi.org\/10.1200\/JCO.2005.05.188.","journal-title":"J Clin Oncol."},{"key":"19070_CR32","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1200\/JCO.2008.18.3228","volume":"27","author":"JM Classe","year":"2009","unstructured":"Classe JM, Bordes V, Campion L, et al. Sentinel lymph node biopsy after neoadjuvant chemotherapy for advanced breast cancer: results of Ganglion Sentinelle et Chimiotherapie Neoadjuvante, a French prospective multicentric study. J Clin Oncol. 2009;27:726\u201332. https:\/\/doi.org\/10.1200\/JCO.2008.18.3228.","journal-title":"J Clin Oncol."},{"key":"19070_CR33","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1097\/SLA.0000000000000551","volume":"261","author":"JC Boughey","year":"2015","unstructured":"Boughey JC, Suman VJ, Mittendorf EA, et al. Factors affecting sentinel lymph node identification rate after neoadjuvant chemotherapy for breast cancer patients enrolled in ACOSOG Z1071 (Alliance). Ann Surg. 2015;261:547\u201352. https:\/\/doi.org\/10.1097\/SLA.0000000000000551.","journal-title":"Ann Surg."},{"key":"19070_CR34","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1097\/SLA.0000000000001375","volume":"263","author":"JC Boughey","year":"2016","unstructured":"Boughey JC, Ballman KV, Le-Petross HT, et al. Identification and resection of clipped node decreases the false-negative rate of sentinel lymph node surgery in patients presenting with node-positive breast cancer (T0\u2013T4, N1\u2013N2) who receive neoadjuvant chemotherapy: results from ACOSOG Z1071 (Alliance). Ann Surg. 2016;263:802\u20137. https:\/\/doi.org\/10.1097\/SLA.0000000000001375.","journal-title":"Ann Surg."},{"key":"19070_CR35","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1097\/SLA.0000000000000558","volume":"261","author":"M Donker","year":"2015","unstructured":"Donker M, Straver ME, Wesseling J, et al. Marking axillary lymph nodes with radioactive iodine seeds for axillary staging after neoadjuvant systemic treatment in breast cancer patients: the MARI procedure. Ann Surg. 2015;261:378\u201382. https:\/\/doi.org\/10.1097\/SLA.0000000000000558.","journal-title":"Ann Surg."},{"key":"19070_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2025.104411","volume":"80","author":"AKE van Hemert","year":"2025","unstructured":"van Hemert AKE, van Loevezijn AA, Baas MPD, et al. Omitting axillary lymph node dissection in breast cancer patients with extensive nodal disease and excellent response to primary systemic therapy using the MARI protocol. Breast. 2025;80:104411. https:\/\/doi.org\/10.1016\/j.breast.2025.104411.","journal-title":"Breast."},{"key":"19070_CR37","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1002\/bjs.10986","volume":"105","author":"SR Tee","year":"2018","unstructured":"Tee SR, Devane LA, Evoy D, et al. Meta-analysis of sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with initial biopsy-proven node-positive breast cancer. Br J Surg. 2018;105:1541\u201352. https:\/\/doi.org\/10.1002\/bjs.10986.","journal-title":"Br J Surg."},{"key":"19070_CR38","doi-asserted-by":"publisher","first-page":"znae008","DOI":"10.1093\/bjs\/znae008","volume":"111","author":"E Pantiora","year":"2024","unstructured":"Pantiora E, Eriksson S, W\u00e4rnberg F, et al. Magnetically guided surgery after primary systemic therapy for breast cancer: implications for enhanced axillary mapping. Br J Surg. 2024;111:znae008. https:\/\/doi.org\/10.1093\/bjs\/znae008.","journal-title":"Br J Surg."},{"key":"19070_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2025.109684","volume":"51","author":"MR Boland","year":"2025","unstructured":"Boland MR, Pantiora E, Rutherford C, et al. Use of superparamagnetic iron oxide for sentinel lymph node detection following neoadjuvant systemic therapy: a systematic review and meta-analysis. Eur J Surg Oncol. 2025;51:109684. https:\/\/doi.org\/10.1016\/j.ejso.2025.109684.","journal-title":"Eur J Surg Oncol."},{"key":"19070_CR40","doi-asserted-by":"publisher","first-page":"3430","DOI":"10.1200\/JCO.20.00459","volume":"38","author":"GE Naoum","year":"2020","unstructured":"Naoum GE, Roberts S, Brunelle CL, et al. Quantifying the impact of axillary surgery and nodal irradiation on breast cancer-related lymphedema and local tumor control: long-term results from a prospective screening trial. J Clin Oncol. 2020;38:3430\u20138. https:\/\/doi.org\/10.1200\/JCO.20.00459.","journal-title":"J Clin Oncol."},{"key":"19070_CR41","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1245\/s10434-019-07400-0","volume":"26","author":"SY Jung","year":"2019","unstructured":"Jung SY, Han JH, Park SJ, et al. The sentinel lymph node biopsy using indocyanine green fluorescence plus radioisotope method compared with the radioisotope-only method for breast cancer patients after neoadjuvant chemotherapy: a prospective, randomized, open-label, single-center phase 2 trial. Ann Surg Oncol. 2019;26:2409\u201316. https:\/\/doi.org\/10.1245\/s10434-019-07400-0.","journal-title":"Ann Surg Oncol."},{"key":"19070_CR42","doi-asserted-by":"publisher","first-page":"znae071","DOI":"10.1093\/bjs\/znae071","volume":"111","author":"SR de Wild","year":"2024","unstructured":"de Wild SR, Koppert LB, van Nijnatten TJA, et al. Systematic review of targeted axillary dissection in node-positive breast cancer treated with neoadjuvant systemic therapy: variation in type of marker and timing of placement. Br J Surg. 2024;111:znae071. https:\/\/doi.org\/10.1093\/bjs\/znae071.","journal-title":"Br J Surg."},{"key":"19070_CR43","doi-asserted-by":"publisher","first-page":"e1621","DOI":"10.1634\/theoncologist.2020-0494","volume":"25","author":"GH Lim","year":"2020","unstructured":"Lim GH, Gudi M, Teo SY, et al. Would removal of all ultrasound abnormal metastatic lymph nodes without sentinel lymph node biopsy be accurate in patients with breast cancer with neoadjuvant chemotherapy? Oncologist. 2020;25:e1621\u20137. https:\/\/doi.org\/10.1634\/theoncologist.2020-0494.","journal-title":"Oncologist."},{"key":"19070_CR44","doi-asserted-by":"publisher","first-page":"2468","DOI":"10.1245\/s10434-014-3775-6","volume":"21","author":"EA Mittendorf","year":"2014","unstructured":"Mittendorf EA, Caudle AS, Yang W, et al. Implementation of the American College of Surgeons Oncology Group z1071 trial data in clinical practice: is there a way forward for sentinel lymph node dissection in clinically node-positive breast cancer patients treated with neoadjuvant chemotherapy? Ann Surg Oncol. 2014;21:2468\u201373. https:\/\/doi.org\/10.1245\/s10434-014-3775-6.","journal-title":"Ann Surg Oncol."},{"key":"19070_CR45","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.3390\/cancers13071539","volume":"13","author":"PK Swarnkar","year":"2021","unstructured":"Swarnkar PK, Tayeh S, Michell MJ, et al. The evolving role of marked lymph node biopsy (MLNB) and targeted axillary dissection (TAD) after neoadjuvant chemotherapy (NACT) for node-positive breast cancer: systematic review and pooled analysis. Cancers Basel. 2021;13:1539. https:\/\/doi.org\/10.3390\/cancers13071539.","journal-title":"Cancers Basel."},{"key":"19070_CR46","doi-asserted-by":"publisher","first-page":"7362","DOI":"10.1245\/s10434-024-15705-y","volume":"31","author":"A Weiss","year":"2024","unstructured":"Weiss A, Colugnati F, Mitchell M, et al. Contemporary axillary surgical management in patients with pathologically node-positive disease after neoadjuvant chemotherapy: a survey of members of the American Society of Breast Surgeons. Ann Surg Oncol. 2024;31:7362\u201371. https:\/\/doi.org\/10.1245\/s10434-024-15705-y.","journal-title":"Ann Surg Oncol."},{"key":"19070_CR47","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.ejso.2022.11.099","volume":"49","author":"Y Park","year":"2023","unstructured":"Park Y, Shin YS, Kim K, et al. Omission of axillary lymph node dissection in patients with ypN+ breast cancer after neoadjuvant chemotherapy: a retrospective multicenter study (KROG 21\u201306). Eur J Surg Oncol. 2023;49:589\u201396. https:\/\/doi.org\/10.1016\/j.ejso.2022.11.099.","journal-title":"Eur J Surg Oncol."},{"key":"19070_CR48","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35610","volume":"131","author":"M Muslumanoglu","year":"2025","unstructured":"Muslumanoglu M, Cabioglu N, Igci A, et al. Combined analysis of the MF18-02\/MF18-03 NEOSENTITURK studies: ypN-positive disease does not necessitate axillary lymph node dissection in patients with breast cancer with a good response to neoadjuvant chemotherapy as long as radiotherapy is provided. Cancer. 2025;131:e35610. https:\/\/doi.org\/10.1002\/cncr.35610.","journal-title":"Cancer."},{"key":"19070_CR49","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1200\/JCO.24.01052","volume":"43","author":"G Montagna","year":"2025","unstructured":"Montagna G, Laws A, Ferrucci M, et al. Nodal burden and oncologic outcomes in patients with residual isolated tumor cells after neoadjuvant chemotherapy (ypN0i+): the OPBC-05\/ICARO study. J Clin Oncol. 2025;43:810\u201320. https:\/\/doi.org\/10.1200\/JCO.24.01052.","journal-title":"J Clin Oncol."},{"key":"19070_CR50","doi-asserted-by":"crossref","unstructured":"Boughey JC. RF2-01. Factors influencing additional nodal disease and pathologic nodal upstaging with axillary dissection in patients with residual node-positive breast cancer after neoadjuvant chemotherapy enrolled on Alliance A011202 clinical trial. In: San Antonio Breast Cancer Symposium, 2024. Available at https:\/\/sabcs.org\/Portals\/0\/Documents\/Formatted_Abstracts%2011-27 .%20Without%20Embargoed.","DOI":"10.1158\/1557-3265.SABCS24-RF2-01"},{"key":"19070_CR51","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1001\/jama.2017.11470","volume":"318","author":"AE Giuliano","year":"2017","unstructured":"Giuliano AE, Ballman KV, McCall L, et al. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial. JAMA. 2017;318:918\u201326. https:\/\/doi.org\/10.1001\/jama.2017.11470.","journal-title":"JAMA."},{"key":"19070_CR52","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1016\/S1470-2045(14)70460-7","volume":"15","author":"M Donker","year":"2014","unstructured":"Donker M, van Tienhoven G, Straver ME, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981\u201322023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014;15:1303\u201310. https:\/\/doi.org\/10.1016\/S1470-2045(14)70460-7.","journal-title":"Lancet Oncol."},{"key":"19070_CR53","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s12957-024-03413-6","volume":"22","author":"N Cab\u0131o\u011flu","year":"2024","unstructured":"Cab\u0131o\u011flu N, Karanl\u0131k H, Y\u0131lmaz R, et al. Targeted axillary dissection reduces residual nodal disease in clinically node-positive breast cancer after neoadjuvant chemotherapy. World J Surg Oncol. 2024;22:178. https:\/\/doi.org\/10.1186\/s12957-024-03413-6.","journal-title":"World J Surg Oncol."},{"key":"19070_CR54","unstructured":"Alliance A11202 trial. Comparison of axillary lymph node dissection with axillary radiation for patients with node-positive breast cancer treated with chemotherapy. ClinicalTrials.gov identifier: NCT01901094."},{"key":"19070_CR55","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1186\/s13063-018-3021-9","volume":"19","author":"G Henke","year":"2018","unstructured":"Henke G, Knauer M, Ribi K, et al. Tailored axillary surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (TAXIS): study protocol for a multicenter, randomized phase-III trial. Trials. 2018;19:667. https:\/\/doi.org\/10.1186\/s13063-018-3021-9.","journal-title":"Trials."},{"key":"19070_CR56","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1056\/NEJMoa1612645","volume":"376","author":"N Masuda","year":"2017","unstructured":"Masuda N, Lee SJ, Ohtani S, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med. 2017;376:2147\u201359. https:\/\/doi.org\/10.1056\/NEJMoa1612645.","journal-title":"N Engl J Med."},{"key":"19070_CR57","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa1814017","volume":"380","author":"G von Minckwitz","year":"2019","unstructured":"von Minckwitz G, Huang CS, Mano MS, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380:617\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1814017.","journal-title":"N Engl J Med."},{"key":"19070_CR58","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","volume":"384","author":"ANJ Tutt","year":"2021","unstructured":"Tutt ANJ, Garber JE, Kaufman B, et al. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N Engl J Med. 2021;384:2394\u2013405. https:\/\/doi.org\/10.1056\/NEJMoa2105215.","journal-title":"N Engl J Med."},{"key":"19070_CR59","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1470-","volume":"24","author":"SRD Johnston","year":"2023","unstructured":"Johnston SRD, Toi M, O\u2019Shaughnessy J, et al. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol. 2023;24:77\u201390. https:\/\/doi.org\/10.1016\/S1470-.","journal-title":"Lancet Oncol."},{"key":"19070_CR60","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1200\/JCO.23.01935","volume":"42","author":"C Valenza","year":"2024","unstructured":"Valenza C, Trapani D, Loibl S, et al. Optimizing postneoadjuvant treatment in patients with early breast cancer achieving pathologic complete response. J Clin Oncol. 2024;42:2372\u20136. https:\/\/doi.org\/10.1200\/JCO.23.01935.","journal-title":"J Clin Oncol."},{"key":"19070_CR61","doi-asserted-by":"publisher","first-page":"5960","DOI":"10.1245\/s10434-021-09897-w","volume":"28","author":"A Weiss","year":"2021","unstructured":"Weiss A, Campbell J, Ballman KV, et al. Factors associated with nodal pathologic complete response among breast cancer patients treated with neoadjuvant chemotherapy: results of CALGB 40601 (HER2+) and 40603 (triple-negative) (Alliance). Ann Surg Oncol. 2021;28:5960\u201371. https:\/\/doi.org\/10.1245\/s10434-021-09897-w.","journal-title":"Ann Surg Oncol."},{"key":"19070_CR62","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMoa2414859","volume":"392","author":"EP Mamounas","year":"2025","unstructured":"Mamounas EP, Bandos H, White JR, et al. Omitting regional nodal irradiation after response to neoadjuvant chemotherapy. N Engl J Med. 2025;392:2113\u201324. https:\/\/doi.org\/10.1056\/NEJMoa2414859.","journal-title":"N Engl J Med."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-19070-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-025-19070-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-19070-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T12:26:51Z","timestamp":1776256011000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-025-19070-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,16]]},"references-count":62,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["19070"],"URL":"https:\/\/doi.org\/10.1245\/s10434-025-19070-2","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,16]]},"assertion":[{"value":"14 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"There are no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}